Market capitalization | $498.16m |
Enterprise Value | $452.69m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 36.92 |
P/S ratio (TTM) P/S ratio | 40.63 |
P/B ratio (TTM) P/B ratio | 8.09 |
Revenue growth (TTM) Revenue growth | 41,184.20% |
Revenue (TTM) Revenue | $12.26m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
5 Analysts have issued a CorMedix Inc forecast:
5 Analysts have issued a CorMedix Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | 12 12 |
40,767%
40,767%
|
|
Gross Profit | 10 10 |
5,761%
5,761%
|
|
EBITDA | -51 -51 |
22%
22%
|
EBIT (Operating Income) EBIT | -51 -51 |
22%
22%
|
Net Profit | -46 -46 |
16%
16%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
CorMedix, Inc. operates as a pharmaceutical and medical device company. The firm seeks to license, develop and commercialize prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. It is developing its product Neutrolin, a novel, non-antibiotic antimicrobial solution designed to prevent costly and dangerous bloodstream infections associated with the use of central venous catheters. The company was founded by Antony E. Pfaffle in 2006 and is headquartered in Berkeley Heights, NJ.
Head office | United States |
CEO | Joseph Todisco |
Employees | 82 |
Founded | 2006 |
Website | www.cormedix.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.